Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 709 Shares

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 709 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $175.07, for a total value of $124,124.63. Following the sale, the insider owned 58,090 shares in the company, valued at $10,169,816.30. The trade was a 1.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Michael Alexander Smith also recently made the following trade(s):

• On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $183,401.01.
• On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $241,968.68.
• On Monday, November 3rd, Michael Alexander Smith sold 27,130 shares of Insmed stock. The shares were sold at an average price of $183.78, for a total transaction of $4,985,951.40.

Insmed Price Performance

Shares of NASDAQ INSM traded down $5.73 during trading on Thursday, reaching $170.27. The company had a trading volume of 2,588,589 shares, compared to its average volume of 2,142,398. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The business’s 50 day moving average price is $190.79 and its 200-day moving average price is $151.24. The stock has a market cap of $36.31 billion, a PE ratio of -27.51 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same period last year, the company earned ($1.27) earnings per share. Insmed’s revenue for the quarter was up 52.4% compared to the same quarter last year. Analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Institutional Trading of Insmed

A number of hedge funds have recently modified their holdings of the company. CIBC Private Wealth Group LLC grew its holdings in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the period. ORG Partners LLC raised its holdings in Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank bought a new position in shares of Insmed during the second quarter worth $28,000. Stone House Investment Management LLC acquired a new position in shares of Insmed in the 3rd quarter valued at $29,000. Finally, SBI Securities Co. Ltd. grew its holdings in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on INSM shares. Redburn Partners set a $263.00 price target on Insmed in a research note on Thursday, December 4th. Rothschild Redb upgraded Insmed to a “strong-buy” rating in a research report on Thursday, December 4th. Wells Fargo & Company set a $195.00 target price on shares of Insmed in a research report on Thursday, December 18th. Royal Bank Of Canada reduced their target price on shares of Insmed from $215.00 to $195.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Finally, HC Wainwright lowered their price target on shares of Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $205.64.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.